Extraction and Isolation
The dried gum resin of G. hanburyi (500 g) was powdered and extracted with EtOAc (3×4 L) at room temperature for two days. The EtOAc extract (350.5 g) was chromatographed on a silica gel column (10 cm ×110 cm) eluted successively with petroleum ether-EtOAc (10:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3; v/v, each 5 L) to obtain ten major fractions. Fraction 4 (11.2 g) was subjected to column (8 cm × 80 cm) chromatography using a gradient of petroleum ether-EtOAc (15:1, 10:1, 6:1; v/v, each 2 L) to afford ten major fractions (4.1-4.10). Fractions 4.4 (1.1 g) and 4.5 (1.6 g) were chromatographed on a silica gel column (4 cm × 45 cm) eluted by petroleum ether-EtOAc/CH 2 Cl 2 -MeOH (12:1, 10:1; 40:1, 30:1 / 100:1, 0:1; v/v, each 1 L), and then purified by semipreparative HPLC on a reversed-phase C 18 column (10 mm × 250 mm, 5 μm) (MeOH-H 2 O / CH 3 CN-H 2 O, 93:7 / 96:4, 86:14, 3 mL/min) to give compounds 3 (30 mg, t R =30 min ), 11 (2 mg, t R =16 min), and 13 (6 mg, t R =18 min); fraction 4.7 (0.4 g) was also purified by repeated semipreparative HPLC on a reversed-phase C 18 column (10 mm × 250 mm, 5 μm) (CH 3 CN-H 2 O, 88:12, 3 mL/min) and Sephadex LH-20 column (1 cm ×40 cm, MeOH, 100%) to give compound 5 (6 mg, t R =86 min); fraction 4.8 (0.1 g) was subjected to semipreparative HPLC on a reversed-phase C 18 column (10 mm × 250 mm, 5 μm) (CH 3 CN-H 2 O-0.08%CF 3 COOH, 75:23:2, 3 mL/min) to afford compound 16 (31 mg, t R =75 min). A portion (100 g) of fraction 5 and 6 was fractionated by a silica gel column (8 cm × 80 cm) eluting with petroleum ether-EtOAc (6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2,1:3; v/v, each 2 L) to obtain twenty fractions (5.1-5.20); fraction 5.12 (0.3 g) was separated by repeated semipreparative HPLC on a reversed-phase C 18 column (10 mm × 250 mm, 5 μm) (CH 3 CN-H 2 O-0.08% CF 3 COOH, 75:23:2, 82:16:2, 3 mL/min) to get compounds 4 (30 mg, t R =29 min) and 10 (30 mg, t R =21 min); fraction 5.14 (1.0 g) was purified by semipreparative HPLC on a reversed-phase C 18 column (10 mm × 250 mm, 5 μm) (CH 3 CN-H 2 O-0.08% CF 3 COOH, 75:23:2, 3 mL/min) to afford compound 14 (5 mg, t R =48 min); fraction 5.16 (0.6 g) was separated by repeated semipreparative HPLC on a reversed-phase C 18 column (10 mm × 250 mm, 5 μm) (CH 3 CN-H 2 O-0.08% CF 3 COOH, 55:43:2, 3 mL/min) to get compound 2 (11 mg, t R =44 min). Fraction 7 (24.1 g) was subjected to column (8 cm × 80 cm) chromatography using a gradient of petroleum ether-EtOAc (5:1, 4:1, 3:1; v/v, each 2 L) and semipreparative HPLC on a reversed-phase C 18 column (10 mm × 250 mm, 5 μm) (CH 3 CN-H 2 O-0.08% CF 3 COOH, 80:18:2, 3 mL/min) to get compound 12 (8 mg, t R =31 min).
Fraction 9 (13.3 g) was fractionated by column (8 cm × 80 cm) chromatography using a gradient of CH 2 Cl 2 -MeOH (50:1, 40:1, 30:1, 15:1; v/v, each 1.5 L) to give five fractions (9.1-9.5); fraction 9.2 (6.7 g) was subjected to column (4 cm × 40 cm) chromatography using a gradient of CH 2 Cl 2 -MeOH (100:1, 70:1; v/v, each 1 L) and semipreparative HPLC on a reversed-phase C 18 column (10 mm × 250 mm, 5 μm) (CH 3 CN-H 2 O-0.08% CF 3 COOH, 72:26:2, 3 mL/min) to yield compounds 6 (4 mg, t R =61 min) and 7 (4.5 mg, t R =65 min); fraction 9.4 (1.7 g) was also purified by column (2.5 cm × 30 cm) chromatography using a gradient of petroleum ether-EtOAc (1.5:1, 1:1; v/v, each 0.5 L) and repeated semipreparative HPLC (MeOH-H 2 O-0.08% CF 3 COOH / CH 3 CN-H 2 O-0.08% CF 3 COOH, 75:23:2 / 85:13:2, 3 mL/min) to get compounds 1 (5 mg, t R =33 min) and 15 (5 mg, t R =23 min). Fraction 10 (4.8 g) was subjected to column (4 cm × 40 cm) chromatography using a gradient of CH 2 Cl 2 -MeOH (50:1, 25:1, 10:1; v/v, each 1 L) and semipreparative HPLC on a reversed-phase C 18 column (10 mm × 250 mm, 5 μm) (CH 3 CN-H 2 O-0.08% CF 3 COOH, 48:50:2, 3 mL/min) to get compounds 8 (8 mg, t R =45 min) and 9 (10 mg, t R =50 min).
Cytotoxicity assay
The cytotoxic activity assay was performed using the MTT method. A549 (human lung carcinoma cell), HCT116 (human colon carcinoma cell), MDA-MB-231 (human breast carcinoma cell) were used. Cells were cultured in DMEM medium with 10% fetal calf serum, penicillin-streptomycin, and non-essential amino acid. Varying concentrations of 0.001, 0.01, 0.1, 1.0, 10, and 100 μg/mL of the isolated compounds (1-16) were prepared from the stock solutions which were dissolved in DMSO by serial dilution in PBS. Each microtiter plate well (96-flat bottom microwell plates) was added with 100 μL of cell lines in fresh medium at 5-6×10 4 cell/mL. Cells were incubated for 24 h in a humidified incubator at 37 °C with an atmosphere of 5% CO 2 . After addition of test solution (10 μL), cells were incubated for 72 h at 37 °C with an atmosphere of 5% CO 2 . Further, 20 μL of 5 mg/mL MTT was added to each well. After 4 h, the unreached dye was removed, the insoluble formazan crystal was dissolved in 100 μL/ well of MTT solvent, and the plate was measured spectrophotometrically in a microplate reader at 570 nm. The IC 50 values found for the test compounds and reference compound were compared. Figure 17S . DEPT135 spectrum of compound (3) Figure 18S . HRMS spectrum of compound (3)
